Literature DB >> 14676100

Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?

Charles F Eisenbeis, Michael A Caligiuri, John C Byrd.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14676100

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

1.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Authors:  Eric F Zhu; Shuning A Gai; Cary F Opel; Byron H Kwan; Rishi Surana; Martin C Mihm; Monique J Kauke; Kelly D Moynihan; Alessandro Angelini; Robert T Williams; Matthias T Stephan; Jacob S Kim; Michael B Yaffe; Darrell J Irvine; Louis M Weiner; Glenn Dranoff; K Dane Wittrup
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.

Authors:  Marco Picardi; Roberta Della Pepa; Claudia Giordano; Irene Zacheo; Novella Pugliese; Chiara Mortaruolo; Fabio Trastulli; Antonio Giordano; Mariano Lucignano; Maria Di Perna; Marta Raimondo; Claudia Salvatore; Fabrizio Pane
Journal:  Blood       Date:  2018-12-07       Impact factor: 22.113

3.  A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.

Authors:  Caroline S Breton; Aimable Nahimana; Dominique Aubry; Julie Macoin; Pierre Moretti; Martin Bertschinger; Samuel Hou; Michel A Duchosal; Jonathan Back
Journal:  J Hematol Oncol       Date:  2014-04-14       Impact factor: 17.388

Review 4.  Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.

Authors:  Eunhee G Kim; Kristine M Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-11-01       Impact factor: 4.634

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.